Introduction {#s0005}
============

The complexity of treatment strategies pertaining to non-metastatic prostate cancer (CaP) is well recognized, necessitating a co-operation between specialist colleagues, but also a significant input from the patients themselves [@b0005]. The dramatic changes in incidence, diagnostic stage and mortality in the last 30 years resulted in modification of medical attitudes and development of a variety of management options (surgery, external-beam radiotherapy, brachytherapy, cryotherapy, high-intensity focused ultrasound, hormonal therapy, active surveillance, watchful waiting). For localized CaP there does not exist a clearly established, universally applied advantage of a given treatment modality over the others; treatment decision is an intricate process that ought to include risk assessment and precise disease extent and topography, amongst other factors.

A need for multidisciplinary involvement and shared decision-making therefore evolved, highlighting the cardinal importance of patient education.

The Gustave Roussy Prostate Cancer Multidisciplinary Clinic (PCMC), inaugurated in March 2011, is a comprehensive weekly clinic for localized or locally advanced CaP patients requesting a second opinion, based on the model of shared decision-making. It offers expert specialist care in a collaboration between Gustave Roussy and the urological surgical teams of the Hôpital Bicêtre and Hôpital Saint Joseph, Paris, France. Access to the PCMC is via general practitioner or specialist referral, or at the patient's own initiative.

This specialist clinic offers patients the opportunity to successively consult with a radiation oncologist and a urological surgeon, part of a dedicated 5-member team. Consultation time for each specialist is 45 min. All cases are discussed at the Genitourinary (GU) Tumor Board on the same day, with the further participation of medical oncologists, specialist and interventional radiologists and histopathologists. The final treatment plan is established at this multidisciplinary meeting. Patients were informed of the Tumor Board recommendation during a follow-up clinic or telephone consultation.

We consider the concept and design of this PCMC to be adapted to the specific setting of localized and locally advanced CaP. We present here an evaluation of the first two years of the Gustave Roussy PCMC activity.

Methods {#s0010}
=======

Patient cohort {#s0015}
--------------

All patients seen in the PCMC clinic were included in the initial register; the following exclusion criteria were applied for the final cohort analysis, aiming for bias elimination:-Absence of histopathological confirmation of prostatic adenocarcinoma.-Pre-treated patients.-Patients not specifically addressed to the PCMC Clinic, seen by a single specialist in regard with a previously established treatment plan.-Patients belonging to Gustave Roussy staff.

Data collection {#s0020}
---------------

The data source was the hospital electronic and paper records and a dedicated questionnaire. Data were collected in a dedicated Excel-based database (Microsoft Inc, Washington, USA). [Table 1](#t0005){ref-type="table"} presents an outline of the recorded data. The patient socioeconomic status was scored according to the French 2003 classification of Professions and Socio-Professional Categories [@b0010]. All PSA measurements and biopsies were performed outside Gustave Roussy prior to the consultation date. The weight and volume of the prostatic gland were estimated based on MRI, CT, ultrasound imaging and clinical examination. The T.N.M. classification was according to the 7th AJCC edition [@b0015]. The clinical T stage was scored based on the information in the medical notes; since the precise T2 stage scoring was available for only a small subset of patients, it was not included in the analysis. Apical involvement and capsular and seminal vesicle involvement were scored based on available information (clinical examination, imaging, localization of positive cores).Table 1Collected data/analysis variables.Personal dataMarital status\
Socio-economic statusConsultation detailsConsultation year\
Initial/s opinion consultation\
Consultation order (surgery/radiotherapy)\
Consulting urologist\
Consulting radiotherapistComorbiditiesCardiovascular disease\
Previous TURP\
Family history of prostate cancerLUTS/sexual dysfunctionIPSS score\
Presence of nocturia\
Presence of hesitancy\
Presence of terminal dribbling\
Presence/quality of erectionPSAPSA valueProstate biopsy: core numberTotal number of cores\
Total number of positive cores\
Number of positive cores in the right lobe\
Number of positive cores in the left lobeProstate biopsy: lengthTotal length of biopsy cores\
Total length of tumour\
Total length of tumour in the right lobe\
Total length of tumour in the left lobeGleason scoreTotal Gleason score\
Primary grade of Gleason score\
Secondary grade of Gleason scoreProstate Weight/VolumeEstimated weight & volume of the prostate glandTNM classificationClinical T stageImagingMRI performed\
Local extension on MRI\
Pathological lymph nodes on MRI\
CT scan performed\
Pathological lymph nodes on CT\
Bone scan performed\
Findings indicative of metastasisMultimodal staging (clinical, biopsy, imaging)Apical involvement\
Capsular infiltration\
Seminal vesicle infiltrationPrognostic stageNCCN stage\
D'Amico classificationProposed treatment plansPre-existing treatment plan (if applicable)\
Consultant urologist proposal\
Consultant radiotherapist proposal\
Multidisciplinary team proposalPatient choiceChosen treatment modality\
Modification of pre-existing choice\
Place of treatment\
Modification of place of treatment

This study was designed as an early service evaluation, and therefore of a short follow-up, so no long-term data on oncologic outcome could be retrieved.

Questionnaire {#s0025}
-------------

The project questionnaire was designed and dispatched via postal mail at two time-points at a 5-month interval, accompanied by an introductory letter and prepaid postage envelope, in accordance with national legislations. The questionnaire enquired upon patient satisfaction, perception of the consultation experience, and aimed to collect complementary information on CaP management after the time of PCMC consultation ([Table S1](#s0055){ref-type="sec"}).

Statistical analysis {#s0030}
--------------------

The reported percentages in the descriptive statistics are estimated on the total number of the cohort (n = 195). The reported percentages relevant to questionnaire responses refer to the total number of received responses, unless otherwise specified. The percentage values were rounded to the nearest unit.

Results {#s0035}
=======

We identified 215 consecutive patients seen in the PCMC clinic during the period March 2011-December 2013. A total of 20 patients were excluded from the analysis as per the above exclusion criteria. The final analysis was performed on 195 patients. Of them, 91 patients consulted in 2011 and 104 patients in 2012. A flowchart of study procedure is shown in [Fig. 1](#f0005){ref-type="fig"}. A total of 134 questionnaires were returned (69%). Question-specific response rates varied greatly (39--68%) ([Table S2](#s0055){ref-type="sec"}). Patient and disease characteristics and consultation specifics are detailed in [Table 2](#t0010){ref-type="table"}.Fig. 1PCMC study consort diagram.Table 2Patient characteristics and consultation specifics.Consultation motive (number,%)[1](#tblfn1){ref-type="table-fn"}, [2](#tblfn2){ref-type="table-fn"} Second opinion84 (62.7) Advice of friends/family39 (29.1) Medical referral21 (15.7) Internet-based information13 (9.7) Inadequate prior information14 (10.4) Consultation order (number,%)[3](#tblfn3){ref-type="table-fn"} Surgeon then radiation oncologist25 (12.8) Radiation oncologist then surgeon129 (66.1) Order not recorded13 (6.7) Joint consultation20 (10.2) Surgeon only3 (1.6) Radiation oncologist only5 (2.6)Age (yrs)[3](#tblfn3){ref-type="table-fn"} Range42--81 Median63.5 Mean63.8 Q159 Q368Age group (number,%)[3](#tblfn3){ref-type="table-fn"} 40--498 (4.1) 50--5945 (23.1) 60--69102 (52.3) 70--8140 (20.5)Prior history (number,%)[4](#tblfn4){ref-type="table-fn"} Cardiovascular disease88 (64.2) TURP10 (7.5) LUTS (number,%)[4](#tblfn4){ref-type="table-fn"} Terminal dribbling26 (24.8) Hesitancy23 (50.0)IPSS score[4](#tblfn4){ref-type="table-fn"} ≤746 (56.1) 8--1936 (43.9) 20--352 (2.4)Prostate volume (cm^3^) [4](#tblfn4){ref-type="table-fn"} Range15--140 Median40T stage[4](#tblfn4){ref-type="table-fn"} T198 (62.4) T249 (31.2) T310 (6.4) T40 (0)Imaging[3](#tblfn3){ref-type="table-fn"} MRI prostate-pelvis144 (73.8) CT abdomen-pelvis57 (29.2) CT & MRI31 (15.9) Bone scan2 (1.0)PSA (ng/ml)[3](#tblfn3){ref-type="table-fn"} Median7.3 \<10139 (71.3) 10--2043 (22.0) ≥2012 (6.2) Unknown1 (0.5)Prostatic biopsies[4](#tblfn4){ref-type="table-fn"} Median number of cores12 Median number of positive cores3 Median tumor length (mm)7 Capsular involvement28 (12) Seminal vesicle involvement14 (7)Gleason score[3](#tblfn3){ref-type="table-fn"} 695 (48.7) 784 (43.1) 7 (3 + 4)65 7 (4 + 3)15 Unknown4 811 (5.6) 91 (0.5) 100 (0) Unknown4 (2.1)D'Amico classification[3](#tblfn3){ref-type="table-fn"} Low risk73 (37.4) Intermediate risk89 (45.7) High risk25 (12.8) Metastatic8 (4.1)[^2][^3][^4][^5]

Treatment proposals during the PCMC consultation depended on disease recurrence risk. Overall, three, two and one options were offered for low, intermediate and high-risk patients, respectively. At the subsequent GU Tumor Board, one or two treatment options were suggested for the majority of low- and intermediate-risk patients, while for high-risk patients a single recommendation was usually made. [Table 3](#t0015){ref-type="table"} gives an account of treatment recommendations by the PCMC specialists and the GU Tumor Board.Table 3PCMC recommended treatment options.Recommended treatment optionsLow risk (n = 72)Active surveillanceSurgeryRTBrachytherapyHT[3](#tblfn6){ref-type="table-fn"}OtherUnknownInitial10 (13.9)24 (33.3)5 (6.9)5 (6.9)0 (0.0)1 (1.4)40 (55.5)Radiation oncologist34 (47.2)60 (83.3)33 (45.8)43 (59.7)0 (0.0)3 (4.2)1 (1.4)Surgeon29 (40.3)51 (70.8)28 (38.9)26 (36.1)0 (0.0)7 (9.7)1 (1.4)MDT26 (36.1)39 (54.2)19 (26.4)32 (44.4)0 (0.0)8 (11.1)1 (1.4)  Intermediate risk (n = 89)Initial3 (3.4)34 (38.2)13 (14.6)2 (2.2)1 (1.1)2 (2.2)49 (55.0)Radiation oncologist2 (2.2)73 (82.0)82 (92.1)18 (20.2)0 (0.0)5 (5.6)0 (0.0)Surgeon1 (1.1)70 (78.6)67 (65.3)16 (17.9)0 (0.0)7 (7.9)3 (3.4)MDT2 (2.2)60 (67.4)50 (56.2)9 (10.1)1 (1.1)8 (9.0)2 (2.2)  High risk (n = 24)Initial0 (0.0)3 (12.5)4 (16.7)0 (0.0)0 (0.0)0 (0.0)18 (75.0)Radiation oncologist0 (0.0)7 (29.2)23 (95.8)0 (0.0)0 (0.0)1 (4.2)0 (0.0)Surgeon0 (0.0)6 (25.0)22 (91.7)0 (0.0)1 (4.2)1 (4.2)0 (0.0)MDT0 (0.0)1 (4.2)21 (87.5)0 (0.0)1 (4.2)3 (12.5)0 (0.0)  Metastatic (n = 8)Initial0 (0.0)0 (0.0)2 (25.0)0 (0.0)1 (12.5)0 (0.0)5 (62.5)Radiation oncologist0 (0.0)0 (0.0)5 (62.5)0 (0.0)3 (37.5)0 (0.0)1 (12.5)Surgeon0 (0.0)0 (0.0)4 (50.0)0 (0.0)2 (25.0)0 (0.0)2 (25.0)MDT0 (0.0)0 (0.0)4 (50.0)0 (0.0)40 (0.0)1 (12.5)  Total (n = 195)[1](#tblfn5){ref-type="table-fn"}, [2](#tblfn7){ref-type="table-fn"}Initial13 (6.7)61 (31.3)24 (12.3)7 (3.6)2 (1.0)4 (2.0)112 (57.4)Radiation oncologist37 (19.0)140 (71.8)143 (73.3)61 (31.3)3 (1.5)12 (6.2)2 (1.0)Surgeon31 (15.9)127 (65.1)121 (62.0)52 (26.7)3 (1.5)18 (9.2)6 (3.1)MDT29 (14.9)104 (53.3)90 (46.1)41 (21.0)6 (3.1)21 (10.8)4 (2.0)[^6][^7][^8]

Concordance rate amongst the PCMC clinic specialists was 96.6%, with complete concordance for all proposals at 67.4% (for patients for which more than one was made). Concordance between the radiation oncologist and Tumor Board was 94.4%, and between the surgeon and Tumor Board was 97.3% (complete concordance rates of 55.8% and 65.4% respectively).

The eventual treatment choices were recorded in the medical files or communicated via the questionnaire for 71% of patients (outlined in [Table S3](#s0055){ref-type="sec"}). The percentages of surgery and radiotherapy (external beam or brachytherapy) choices did not differ (29.2% and 29.8% respectively). The final patient choice was in agreement with the Tumor Board recommendation in 93.4%; concordance was 93.4% and 84.5% with the surgeon and radiation oncologist proposals, respectively.

Since this was a second-opinion consultation, all patients had previously seen a urological surgeon elsewhere, and had an established histological diagnosis and a provisional treatment plan. More than half of responding patients (55%) reported that, during their Gustave Roussy PCMC consultation, they were offered treatment options not considered during their initial consultation. Patient satisfaction rate was almost absolute, with 114 of 118 (96.6%) and 4 of 118 (3%) of responding patients reporting complete and moderate satisfaction, respectively. The great majority of responders (122 of 125, 97.6%) felt better informed, either entirely or moderately, while two patients did not feel so, and one patient failed to give an informative answer. The double consultation was found useful by 96.1% of responding patients. The PCMC consultation led to modification of treatment decision in 46% of responding patients, against 26% for whom the consultation did not lead to change of their treatment choice, while 29% of patients had not yet taken their final decision at the end of PCMC consultation. Importantly, 89.3% of patients reported feeling active participants in the decision-making process, while all patients reported satisfaction (97% entirely, 3% moderately) from their PCMC consultation.

Discussion {#s0040}
==========

The PCMC proposes an interdisciplinary consultation time with emphasis on management options and patient choice. It is a time of information, reflection and decision-making. The participating oncology specialists practice different therapeutic modalities and therefore have distinct medical cultures. These double, long, expert consultations serve to optimize provision of specialist information and care. The diversity of provided information, if moderate and not contradictory, may act to facilitate the reflection process of the patient. The sequential consultations with the two specialists, frequently accompanied by his family, feature the patient himself in the centre of the action as the common denominator.

This shared decision-making is a multilevel process influenced by several factors, such as history of cardiovascular disease or recent transuretheral resection of the prostate (TURP). The nature and severity of urinary symptoms also influence management decisions; surgery allows for improvement of obstructive symptoms, whilst radiotherapy (either brachytherapy or external beam irradiation) might worsen them. Irritative symptoms frequently worsen after radiotherapy, while surgery is associated with increased risk of urinary incontinence [@b0020]. Their assessment equally allows for decision on the indication for symptomatic medical treatment or a combined modality.

Interestingly, the median age of our cohort (63.5 years) was significantly lower than the national median for CaP diagnosis (70 years) [@b0025], indicating that younger patients were more actively seeking a second opinion and participation in the decision-making process [@b0030].

It ought to be highlighted that the few *de novo* metastatic patients were purposefully not excluded from our analysis ([Table 2](#t0010){ref-type="table"}), although they represent a minority of patients in our cohort as the PCMC clinic was designed for patients with localized and locally advanced disease. In the era of changing paradigm for *de novo* metastatic CaP [@b0035], [@b0040], [@b0045], lymph-node only pelvic disease or even oligometastatic patients may benefit from a primary locoregional treatment alone or in combination with upfront systemic therapy and could therefore derive benefit from consulting early after diagnosis with specialists involved in locoregional treatments.

The main limitations of our study include memory bias (questionnaires dispatched at an average of two years after the consultation), information bias (the measured outcome was subject to receiving a written response), and associated selection bias, as the obtained answers may not be representative of the cohort (patients with stronger opinions are generally more likely to respond). A further bias could refer to the order of specialist consultations; indeed for clinic scheduling purposes the majority of patients consulted with the radiation oncologist first followed by the surgeon (129 patients, 66%). That could lead to under-representation of certain aspects of clinical elements pertaining to the decision-making, should it was felt that they might have been sufficiently exposed in the preceding consultation.

The concordance rates amongst specialists and Tumor Board were highly satisfactory. Although the input of a medical oncologist was obtained in the GU Tumor Board discussion, the presence of a medical oncologist in the PCMC consultation itself would optimize management both for localized CaP and for newly-diagnosed metastatic patients [@b0050], and most likely further improve the concordance rates between PCMC and Tumor Board, as well as enrich the discussions regarding potential participation in novel agent trials, as the latter have now moved forward to the early and newly-diagnosed disease stages [@b0055], [@b0060].

Further means of improving the PCMC consultation quality and efficiency would be the inclusion of a specialist GU oncology nurse [@b0065]. Their role would entail providing patients with relevant information packages prior to the consultation, preparing patients for better benefiting from their consultation experience, but also discussing and outlining the consultation outcome and obtaining patient feedback at the end of the double consultation. A dedicated PCMC information site within the Gustave Roussy website is also planned; the option of electronically completing the questionnaire could also be included, as a means of improving response rates. Finally, development of a standardized proforma for data capture during the PCMC consultation would aid towards obtaining more complete and homogeneous clinical data via improving intra- and inter-examiner reliability.

Previous published evidence on interdisciplinary consultations offers important knowledge on the value, function and challenges of such specialized clinics [@b0030], [@b0065], [@b0070], [@b0075], [@b0080], [@b0085], [@b0090], [@b0095], [@b0100], [@b0105]. A significant feature of our PCMC is the sequential nature of the specialist consultation, as opposed to a single joint consultation. This offers a diversity of scientific rationale and improved quality of provided information, aids in the integration and processing of information, but also further reinforces the validity of therapeutic proposals; conversely, the patient would more easily appreciate any inconsistencies in the proposed treatment plan(s).

Conclusion {#s0045}
==========

The evaluation of the first years of the Gustave Roussy PCMC indicated high levels of patient satisfaction and a perceived sense of being better equipped to make their final decision on treatment. The double specialist consultation received significant appreciation, providing patients with valid scientific approaches and management details, but also enhancing confidence in the recommendations towards finalizing a treatment plan, and providing them with a feeling of active participation.

Appendix A. Supplementary data {#s0055}
==============================
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[^1]: Co-primary authors.

[^2]: Estimated for the total of returned questionnaires (n = 134).

[^3]: More than one answer to this question was possible.

[^4]: Estimated for the total of analyzed patients (n = 195).

[^5]: Estimated for the total of patients for whom relevant information was recorded.

[^6]: Percentages in brackets refer to the respective (sub-)cohort total.

[^7]: The total cohort number includes the 2 patients whose prostate cancer diagnosis was on TURP.

[^8]: HT refers to hormonal treatment alone, while hormonal treatment (short or long course) combined with RT is included in the RT group.
